Riskpilot← Back to searchSign inGet full accessNN Farmaci AB
ABActiveOrg 5593739674Krögers Promenad 11Retail sale of pharmaceutical products · NACE 4773Est. 20223 employees
Revenue 2025
SEK 28,1M
+3% vs 2024
EBITDA margin
0.3%
-88% vs 2024
Equity ratio
17.6%
Financial strength
Net profit 2025
SEK 58K
-78% vs 2024
| Revenue | SEK 28,1M | +3% |
| EBITDA | SEK 92K | -88% |
| Net profit | SEK 58K | -78% |
| Total assets | SEK 6,9M | -5% |
| Equity | SEK 1,2M | -52% |
| Employees | 3 | — |
Legal name
NN Farmaci AB
Org number
5593739674
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
4 april 2022
Share capital
SEK 25 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget ska bedriva öppenvårdsapotek. Handel med receptbelagda- och receptfria läkemedel och därmed förenlig verksamhet.
Address
Krögers Promenad 11
Email
esmaeili.nima94@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 5 234 | 22 333 | 27 389 | 28 110 |
| Staff expenses | −237 | −2 138 | −2 291 | −2 733 |
| EBITDA | 1 663 | 3 235 | 793 | 92 |
| Depreciation & amort. | −77 | −246 | −248 | −252 |
| EBIT | 1 587 | 2 990 | 546 | −160 |
| Net financials | −47 | −78 | −76 | −9 |
| Profit before tax | 1 136 | 2 166 | 349 | 132 |
| Tax | −236 | −454 | −86 | −74 |
| Net profit | 900 | 1 712 | 263 | 58 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4 804 | 6 976 | 7 210 | 6 858 |
| Equity | 925 | 2 637 | 2 501 | 1 209 |
| Long-term debt | 2 164 | 295 | 27 | 800 |
| Short-term debt | 1 310 | 2 893 | 3 412 | 3 881 |
| Total debt | 3 475 | 3 189 | 3 440 | 4 681 |
EBITDA margin
0.3%
This company
15.8%
Market median
-98% vs market
20222025
Equity ratio
17.6%
This company
38.2%
Market median
-54% vs market
20222025
Return on equity
4.8%
This company
18.4%
Market median
-74% vs market
20222025
Net profit margin
0.2%
This company
8.1%
Market median
-98% vs market
20222025
Asset turnover
4.10×
This company
1.12×
Market median
+266% vs market
20222025
Debt / equity
4.67×
This company
0.62×
Market median
-653% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-04-04 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JO | Audit | 2025 |
NE Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NN Farmaci AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Olof Kristofer Hultman | Audit | 0 companies |
| Nima Esmaeili | Chief Executive Officer | 0 companies |
| Nasim Khorasani | Chairman | 0 companies |
| Abbass Khorasani | Deputy Board Member | 0 companies |
| Nastaran Khorasani | Deputy Board Member | 0 companies |